Bio-Rad (BIO) Q2 2023: Process Chromatography Down Mid-Teens, Diagnostics Outpaces Life Science Recovery
Process chromatography, a key bioprocessing consumables segment, delivered a mid-teens revenue decline, forcing Bio-Rad to reset full-year expectations and highlight diagnostics as the anchor for near-term growth. The company’s updated guidance reflects a sharper biopharma downturn, persistent China headwinds, and a shift in product mix that pressures margins. Investors should focus on diagnostics momentum, inventory normalization, and the timing of biopharma recovery as core levers for the next several quarters.
Summary
- Biopharma Drag Intensifies: Prolonged order push-outs in process chromatography deepen Life Science headwinds.
- Diagnostics Anchors Growth: Clinical diagnostics strength, especially in Asia, offsets life science softness.
- Margin Pressure Persists: Unfavorable mix and inflationary costs weigh on profitability, with recovery timing uncertain.
Business Overview
Bio-Rad Laboratories develops and sells products for life science research and clinical diagnostics. The business operates in two primary segments: Life Science Group, supplying instruments, reagents, and consumables for research and biopharma; and Clinical Diagnostics Group, providing systems and tests for disease screening, blood typing, and monitoring. Revenue is generated through instrument sales, recurring reagent and consumable pull-through, and service contracts. The diagnostics segment is the larger contributor, with biopharma and process chromatography representing a smaller but strategically important portion of the mix.
Performance Analysis
Bio-Rad’s Q2 results underscore a clear divergence between diagnostics strength and biopharma weakness. The company’s total revenue declined slightly on a reported basis, but core revenue (excluding COVID-related sales) grew modestly, driven by robust demand in clinical diagnostics and continued traction in academic markets for life sciences. The standout drag came from process chromatography, bioprocessing consumables used by biopharma manufacturers, which posted a mid-teens revenue decline and now anchors a more cautious outlook for the Life Science Group.
Within Life Science, droplet digital PCR (ddPCR), a high-sensitivity genetic analysis platform, delivered strong double-digit growth, buoyed by the QX600 system rollout and healthy academic demand. However, these gains were not enough to offset biopharma order delays and China macro softness. Diagnostics outperformed, led by diabetes and immunohematology systems, particularly in Asia. Gross margin erosion reflected a less favorable mix, higher logistics and material costs, and inventory reserves, with operating margins falling as a result.
- Process Chromatography Decline: Mid-teens drop in revenue as biopharma customers delayed orders and reduced inventory.
- Diagnostics Outperformance: Asia Pacific, especially China, drove double-digit growth, with diabetes and blood typing franchises leading.
- Gross Margin Compression: Mix shift toward instruments, inflationary input costs, and inventory build weighed on profitability.
Inventory levels remain elevated, reflecting both the diagnostics manufacturing transition and weaker life science demand, with normalization expected over the coming quarters. Operating cash flow improved YoY, but capex and buybacks constrained the net cash position.
Executive Commentary
"We experienced ongoing strong demand for our clinical diagnostic products, contrasted by further softening of demand in the biopharma segment of our life science business. The net result was a more modest growth of our overall core business than expected."
Andy Last, Executive Vice President & Chief Operating Officer
"Given the current market outlook, we are revising our 2023 financial outlook as follows. We now guide currency neutral revenue growth in 2023 to be approximately 80 basis points versus about 4.5% previously."
Alon Daskal, Executive Vice President & Chief Financial Officer
Strategic Positioning
1. Diagnostics as the Growth Anchor
Clinical diagnostics is now the primary engine for Bio-Rad’s top-line stability, with diabetes and immunohematology systems seeing strong placements and reagent pull-through. The diagnostics backlog is being worked down as the Singapore manufacturing site ramps up, providing improved visibility for the second half and into 2024.
2. Life Science: Academic and ddPCR Strength vs. Biopharma Weakness
Life Science Group’s performance is bifurcated: academic and digital PCR markets are resilient, but biopharma demand, especially for process chromatography, is under significant pressure. The QX600 ddPCR platform is gaining traction, but cannot fully offset the loss in bioprocessing consumables. Management views the biopharma downturn as transitory, but is not expecting recovery until at least 2024.
3. China: Macro Uncertainty and Cautious Forecasting
China remains a swing factor across both segments. Diagnostics benefited from reopening tailwinds and robust demand in H1, but management is cautious about H2 given macroeconomic softness. Life Science demand in China continues to lag, with no near-term recovery assumed in guidance.
4. Cost Control and Capital Allocation Discipline
SG&A spend was tightly managed, staying flat YoY despite inflationary pressures. Bio-Rad continues to prioritize operating discipline, with a new $500M share repurchase authorization reflecting confidence in long-term value. Inventory normalization and cost leverage from the Singapore site are expected to support margin stabilization in 2024.
5. Product Mix and Margin Headwinds
Unfavorable mix toward instruments over reagents, along with inflation and inventory reserves, drove gross margin compression. While some of these pressures are transitory, management does not expect a rapid margin rebound until product mix normalizes and biopharma demand returns.
Key Considerations
This quarter marks a strategic reset for Bio-Rad, with diagnostics now the stabilizing force and biopharma recovery pushed further out. Investors should watch the following:
Key Considerations:
- Process Chromatography Order Push-Outs: Delayed biopharma orders are not expected to rebound in 2023, capping Life Science growth.
- Diagnostics Momentum: Strong diabetes and blood typing placements, especially in Asia, underpin near-term revenue growth.
- China Volatility: Both segments face macro headwinds, with diagnostics benefiting from reopening but life science still weak.
- Margin Recovery Path: Margin pressure from mix and costs is likely to persist until biopharma stabilizes and Singapore ramp is complete.
- Capital Allocation: New $500M buyback authorization signals management’s conviction in intrinsic value and balance sheet strength.
Risks
Bio-Rad’s outlook is clouded by persistent biopharma softness, especially for process chromatography, and ongoing macro uncertainty in China. Gross margin is vulnerable to further mix shifts and inflationary input costs, while inventory normalization could take several quarters. Any further deterioration in biopharma funding or a slower-than-expected diagnostics ramp in Asia would add downside risk. Regulatory or competitive dynamics in diagnostics, as well as potential volatility from the Sartorius equity stake, also warrant monitoring.
Forward Outlook
For Q3 and Q4, Bio-Rad guided to:
- About 4% YoY core revenue growth in the second half (vs. 5.4% in H1)
- Non-GAAP gross margin of ~54.5% for H2
- Operating margin of ~18% for H2 (down from prior 21% guide)
For full-year 2023, management lowered guidance:
- Currency-neutral revenue growth to ~0.8%
- Core revenue growth ex-COVID to ~4.5% (was 8.5%)
- Diagnostics group core growth to ~5.5%
- Life Science group revenue decline of ~4% (ex-COVID, +4%)
Management cited ongoing biopharma order delays, China macro caution, and unfavorable product mix as key drivers behind the guidance reset. Diagnostic backlog reduction and Singapore ramp are expected to support H2 execution, but biopharma visibility remains low.
- Biopharma recovery not expected until 2024
- Diagnostics backlog normalization targeted by year-end
Takeaways
Bio-Rad’s Q2 confirms diagnostics as the stabilizer amid biopharma turbulence, with process chromatography order delays and China caution forcing a more conservative stance. Investors should focus on execution in diagnostics, inventory normalization, and signs of biopharma stabilization as the key forward levers.
- Diagnostics Outperformance: Growth in diabetes and blood typing systems, particularly in Asia, is offsetting Life Science underperformance.
- Biopharma Headwinds: Delayed process chromatography orders and funding constraints in emerging biotech continue to drag results and outlook.
- Margin Watch: Mix-driven margin pressure and inflation are likely to persist; normalization depends on biopharma recovery and Singapore ramp-up.
Conclusion
Bio-Rad’s growth engine has pivoted to diagnostics, with biopharma and process chromatography now a multi-quarter headwind. Execution on backlog reduction, cost control, and diagnostics momentum will determine near-term performance, while investors must wait for clearer signals of biopharma recovery into 2024.
Industry Read-Through
Bio-Rad’s results reinforce a sector-wide bioprocessing slowdown, with order delays and inventory reductions echoing across life science tools and consumables providers. Diagnostics demand remains resilient, especially in chronic disease and transfusion medicine, but China macro caution is a growing theme for all medtech and life science players. Gross margin pressure from mix and inflation is not unique to Bio-Rad, and investors should scrutinize product mix, regional trends, and capital allocation discipline across the peer group. The timing of biopharma recovery and normalization of China demand will be key sector catalysts into 2024.